The Scientist

» industry and immunology

Most Recent

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

1 Comment

image: Thermo Fisher to Acquire FEI

Thermo Fisher to Acquire FEI

By | June 1, 2016

In a $4.2 billion deal, the science equipment giant is buying the Hillsboro, Oregon-based electron microscope maker.

0 Comments

image: Contributors

Contributors

By | June 1, 2016

Meet some of the people featured in the June 2016 issue of The Scientist.

0 Comments

image: Do Patents Promote or Stall Innovation?

Do Patents Promote or Stall Innovation?

By | June 1, 2016

A petition recently filed with the Supreme Court triggers renewed debate about the role of patents in the diagnostics sector.

3 Comments

image: Enhancing Vaccine Development

Enhancing Vaccine Development

By | June 1, 2016

Using proteomics methods to inform antigen selection

1 Comment

Member, Department of Immunology, St. Jude Children’s Research Hospital. Age: 43

0 Comments

image: Toward Targeted Therapies for Autoimmune Disorders

Toward Targeted Therapies for Autoimmune Disorders

By | June 1, 2016

Training the immune system to cease fire on native tissues could improve outcomes for autoimmune patients, but clinical progress has been slow.

1 Comment

image: E.U. Delays Vote on Roundup

E.U. Delays Vote on Roundup

By | May 24, 2016

Newly published research on the key ingredient in the Monsanto-made weed killer is holding up lawmakers’ decisions on whether to continue to allow its sale in Europe.

4 Comments

The US Department of Agriculture orders Santa Cruz Biotechnology to pay a $3.5 million fine and to cease selling research antibodies.

0 Comments

image: FDA Approves Bladder Cancer Immunotherapy

FDA Approves Bladder Cancer Immunotherapy

By | May 23, 2016

The US Food and Drug Administration greenlights Roche’s Tecentriq, which blocks a protein that obstructs the immune system’s ability to fight cancer.

0 Comments

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS